

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/084,706
Filing Date	February 26, 2002
First Named Inventor	Rasmussen, et al.
Group Art Unit	1647
Examiner Name	J. Seharaseyon
Attorney Docket Number	0228us410

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

RECEIVED

DEC 12 2002


TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS


Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
JS	1	EP	0 287 075	B2	Dr. Rentschler Biotechnologie GmbH	10/19/1988		X
JS	2	EP	0 287 075 (English language translation of document AY)	B2	Dr. Rentschler Biotechnologie GmbH	10/19/1988		
JS	3	WO	01/15736	A2	Maxygen ApS	03/08/2001		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
JS	4	O'CONNELL, et al., "The Influence of Flanking Sequences on O-Glycosylation", <i>Biochemical and Biophysical Research Communications</i> , 1991, pp. 1024-1030, 180:2.	

Examiner Signature		Date Considered	3/21/05
-----------------------	---	--------------------	---------

\*EXAMINER Initial if reference considered; whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



**COPY FROM PATENT**

(Modified) PTO/SB/08A-B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/648,569- 10/084,706
Filing Date	August 25, 2000 icb dk, 2002
First Named Inventor	A. H. Pedersen Rasmussen P.B.
Group Art Unit	1647
Examiner Name	J. Seharaseyon
Attorney Docket Number	0202us810- 0228us410

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
JS	1	5,206,344		Katre et al.	04/27/1993	
JS	2	5,738,846		Greenwald et al.	04/14/1998	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
JS	3	EP	0 370 205	A2	Kyowa Hakko Kogyo Co., Ltd.	05/30/1990		
	4	EP	0 529 300	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		x
	5	EP	0 529 300 (English language translation of document #4)	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		
	6	WO	95/27502	A1	Research Develop- ment Foundation	10/19/1995		
	7	WO	98/35026	A1	Novo Nordisk A/S	08/13/1998		
JS	8	WO	99/55377	A2	Applied Research Systems	11/04/1999		

RECEIVED

NOV 10 2002

TECH CENTER 1600/2901

**OTHER ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
JS	9	Derwent Abstract 042452872 for WO 98/48018, a German publication cited in previous IDS Form-1449.	
JS	10	Derwent Abstract 009442954 for EP 539 300, a French publication cited in previous IDS Form-1449.	

Examiner Signature		Date Considered	3/31/05
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Best Available Copy



(Modified) PTO/SB/08A-B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

**COPY FROM PARENT**

Complete if Known

Application Number 09/648,569 10/084 706  
Filing Date August 25, 2000 02/26/02  
First Named Inventor Anders Hjelholt Pedersen Rasmussen  
Group Art Unit 1633-1647  
Examiner Name Unassigned J. Scharaseyon  
Attorney Docket Number 21-107600US 022805410

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
<input checked="" type="checkbox"/>	AA	4,588,585		Mark et al.	05-13-1986	
	AB	4,686,191		Itoh et al.	08-11-1987	
	AC	4,769,233		Bell et al.	09-06-1988	
	AD	4,904,584		Shaw	02-27-1990	
	AE	4,914,033		Bell et al.	04-03-1990	
	AF	4,917,888		Katre et al.	04-17-1990	
	AG	4,966,843		McCormick et al.	10-30-1990	
	AH	5,218,092		Sasaki et al.	08-06-1993	
	AI	5,376,567		McCormick et al.	12-27-1994	
	AJ	5,382,657		Hoffmann-La Roche Inc.	01-17-1995	
	AK	5,545,723		Goelz et al.	08-13-1996	
<input checked="" type="checkbox"/>	AL	5,795,779		McCormick et al.	08-18-1998	

RECEIVED

NOV 15 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
<input checked="" type="checkbox"/>	AM	WO	95/25170		Biogen, Inc.	09-21-1995		
	AN	WO	98/48018		Fraun-Hofer-Gesellschaft Zur Forderung Der Angewandten	10-29-1998		
	AO	WO	99/03887		Bolder Biotechnology	01-28-1999		
	AP	WO	99/55377		Applied Research	11-04-1999		
			99/01291		Immunex Corporation	12-29-1999		
<input checked="" type="checkbox"/>	AR	WO	00/23114		Biogen, Inc.	04-27-2000		

Examiner Signature

*[Signature]*

Date Considered

3/21/05

EXAMINER Initial: if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Best Available Copy



COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)	Substitute for form 1449A-B/PTO		Complete if Known	
	Application Number	09/648,569 - 10/094 706		
	Filing Date	August 25, 2000 02/26/02		
	First Named Inventor	Anders Hjelholt Pedersen - Kasumussen		
	Group Art Unit	1633-7647		
	Examiner Name	Unassigned J. Scharschewski		
	Attorney Docket Number	31-107600US- 0228 US 410		

AS	WO	00/23472	Biogen, Inc.	04-27-2000	
AT	WO	00/26354	Novo Nordisk	05-11-2000	
AU	EP	083 069	Kyowa Hakko Kogyo Co., Ltd.	09-16-1987	
AV	EP	041 313	Biogen, inc.	09-12-1990	RECEIVED
AW	EP	229 108	Cetus Corporation	12-27-1990	NOV 15 2002
AX	EP	260 350	Cetus Corporation	02-12-1992	TECH CENTER 1600/2900
AY	EP	287 075	Arzneimittelforschung /Drug Research	01-18-1995	
AZ	EP	539 300	Philippe Thiriet	02-07-1996	
BA	EP	593 868	Hoffmann-La Roche Inc.	04-15-1998	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
S	BB	Fierlbeck et al., "Neutralising interferon $\beta$ antibodies in melanoma patients treated with recombinant and natural interferon $\beta$ " <u>Cancer Immunol Immunother</u> (1994) 39:263-268	
	BC	Karpusas et al., "The Structure of Human Interferon- $\beta$ : Implications for activity" <u>CMLS</u> 54 (1998) 1203-1216	
	BD	Karpusas et al. "The crystal structure of human interferon $\beta$ at 2.2 A resolution" <u>Proc. Nat. Acad. Sci. USA</u> (1997) 94:11813-11818	
	BE	Mayorga et al., "Antibodies to Commercially Available Interferon-Bet Molecules in Multiple Sclerosis Patients Treated with Natural Interferon-Beta" <u>Int. Arch. Allergy Immunol</u> 1999; 118:368-371	
	BF	Munschauer et al., "Managing Side Effects of Interferon-Beta in Patients with Relapsing-Remitting Multiple Sclerosis" <u>Clinical Therapeutics</u> vol. 19, No. 5, 1997 883-893	
	PG	Reichlin et al., "Antibodies to human interferon biologic activity recognizing a linear epitope: Analysis by synthetic peptide mapping" <u>Proc. Natl. Acad. Sci. USA</u> vol. 88, pp. 4040-4044 May 1991	

Examiner Signature	Date Considered
	3/31/05

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Best Available Copy



COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/648,569- 10/084,706
Filing Date	August 25, 2000 02/26/02
First Named Inventor	Anders Hjelholt Pedersen Rasmussen
Group Art Unit	1633 1647
Examiner Name	Unassigned J. Seharaseyan
Attorney Docket Number	31-107600US- 022803410

BH	Rudick et al., "Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis" <u>Neurology</u> May 1889, 50: 1266-1272
BI	Runkel et al., "Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon- $\beta$ (IFN- $\beta$ )" <u>Pharmaceutical Research</u> vol. 15, No 4, 1998, 641-649
BJ	Runkel et al, 1998, Jour. Biol. Chem. Difference in Activity between $\alpha$ and $\beta$ Type I Interferons Explored by Mutational Analysis" 273, No. 14, pp. 8003-8008
BK	Senda et al., "Refined Crystal Structure of Recombinant Murine Interferon- $\beta$ at 2.15 A Resolution" <u>J. Mol. Biol.</u> (1995) 253, 187-207
BL	Stewart et al, DNA "Chemical Mutagenesis of Human Interferon- $\beta$ : Construction, Expression in E. coli, and Biological Activity of Sodium Bisulfite-Induced Mutations Vol 6 no 2 1987 p119-128
BM	Taniguchi, et al., "The nucleotide sequence of human fibroblast interferon cDNA" <u>Gene</u> 10 (1980) 11-15
BN	Yong et al., "Interferon beta in the treatment of multiple sclerosis" <u>Neurology</u> 1998; 51: 682-689

Best Available Copy

RECEIVED

NOV 15 2002

TECH CENTER 1600/2900

Examiner  
Signature

Date  
Considered

3/31/03

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.